MetaCap

Aspire-Lakewood (ASBP) vs Chemomab Therapeutics (CMMB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aspire-Lakewood (ASBP) has outperformed Chemomab Therapeutics (CMMB) over the past year, gaining 83.8% versus a loss of 53.0%. Aspire-Lakewood is the larger company by market cap ($10.0 million vs $9.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ASBP+83.76%CMMB-52.96%
+150%+21%-108%
Nov 21, 20251 yearNov 20, 2026
ASBP-98.22%CMMB-92.19%
+36%-35%-106%
Apr 11, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ASBP versus CMMB key metrics
MetricASBPCMMB
Share price$7.13$1.19
Market cap$10.00M$9.58M
1-day change-5.44%+4.39%
YTD return+35.04%-27.88%
1-year return+83.76%-52.96%
5-year return—-96.65%
EPS (TTM)$-30.89$-1.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.20K—
Net income (latest FY)$-24.48M$-8.99M
Gross margin-1.87%—
Operating margin-312016.95%—
Net margin-394725.06%—
52-week high$9.50$2.99
52-week low$0.11$0.92
Distance from 52-week high-24.95%-60.20%
Analyst consensus—none
Avg. price target upside—+320.17%
Average volume29.24K102.39K
Shares outstanding1.40M8.05M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ASBP has outperformed CMMB by 136.7 percentage points over the past year.

About Aspire-Lakewood

ASBP stock →

Aspire-Lakewood Holdings, Inc. develops sublingual drug delivery technology and manufactures automotive and industrial control systems.

Health Care · Biotechnology: Pharmaceutical Preparations

About Chemomab Therapeutics

CMMB stock →

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.

Health Care · Biotechnology: Pharmaceutical Preparations

ASBP vs CMMB FAQ

Which is bigger, Aspire-Lakewood or Chemomab Therapeutics?

Aspire-Lakewood (ASBP) is larger, with a market capitalization of $10.00M compared with $9.58M for Chemomab Therapeutics (CMMB).

Which stock has performed better over the past year, ASBP or CMMB?

ASBP returned +83.76% over the past 12 months, compared with -52.96% for CMMB (price return, excluding dividends). Past performance does not predict future results.

Are Aspire-Lakewood and Chemomab Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons